CClinicalTrials.gg
RecruitingNCT06021301iPRFandMNUpdated Nov 8, 2023

Injectable Platelet-Rich Fibrin and Microneedling For Papillae Reconstruction In Esthetic Zone

A Phase 2 interventional study of Platelet-Rich Fibrin and Microneedling in Injectable Platelet Rich Fibrin and Microneedling in Papilla Reconstruction and Interdental Papillae Reconstruction, sponsored by Cairo University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Cairo University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Sex
All
01

Study summary

The currently available non-surgical techniques for papillary reconstruction did not provide long term maintenance of papillary regeneration, Surgical techniques are invasive and the results are unpredictable . The study is based upon the positive effects of iPRF upon enhancing wound healing in terms of new collagen formation, angiogenesis and increasing keratinized tissue phenotype . iPRF exhibited comparable effects to subepithelial connective tissue graft in papillary reconstruction . The effect of microneedling on the tissue responds as if experiencing tissue trauma and the body's own collagen production is induced to preserve tissue integrity . Growth factors are released immediately after injury, inducing the proliferation of new cells, and fibroblasts are transformed into collagen and elastin fibres from day 5 up to week 8 .

Read the detailed description

The patients diagnosed with black triangles according to Norland classification system for loss of papillary height will be selected. Each patient will receive a proper knowledge of the study protocols along with full-mouth scaling and root planing (SRP) using ultrasonic and hand instruments and will be given personalized oral hygiene instructions. After oral prophylaxis and baseline measurements of insufficient interdental papilla the treatment will be MN and iPRF. First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm. Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively. The final clinical photographs and measurements will recorded 3 and 6 months of last dose administered . After the intervention, patients will receive oral hygiene instructions that include the roll technique when brushing without the use of floss and toothpick during the study period to minimize trauma to the treated site .

02

Conditions studied

  • Injectable Platelet Rich Fibrin and Microneedling in Papilla Reconstruction
  • Interdental Papillae Reconstruction
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Nonsmoking patients aged above 18 years.
  • At least one site with interdental papilla recession in the anterior region of the maxillary or mandibular jaws.
  • The distance from the contact point to alveolar bone is crest \< 7 mm.
  • Class I or Class II papillary recession, according to Nordland and Tarnow's classification systems (Nordland et al., 1998).
  • No active periodontal diseases and good oral hygiene.

Exclusion criteria

Exclusion Criteria:

  • Patients were excluded from the study if they have:
  • Spacing or crowding between the teeth to be treated
  • Abnormal tooth shape
  • Systemic diseases such as diabetes mellitus, hypertension or conditions that alter the outcome of periodontal therapy.
  • In addition, patients will be excluded if they are Pregnant and lactating women.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    iPRF and Microneedling

    First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.

    Other: Platelet-Rich Fibrin and Microneedling

Interventions

  • OtherPlatelet-Rich Fibrin and Microneedling

    First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.

06

What researchers measure

Primary outcomes

  1. Papillary height

    using UNC probe from papillary tip till incisal edge.

    Time frame: at 3,6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06021301
Lead sponsor
Cairo University
Responsible party
Yasmeen Saleh Tolba (Resident at Faculty of Oral and Dental medicine, Cairo University., Cairo University) — Principal investigator
First posted
Sep 1, 2023
Start date
Nov 2023 (estimated)
Primary completion
Apr 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Nov 8, 2023

Study contacts

yasmeen tolba, Resident
Contact
yasmeen.tolba@dentistry.cu.edu.eg
01027453609
yasmeen tolba, Resident
principal investigator · department of periodontology ,cairo university

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion